

DATE: April 1, 2021
TO: All Well Sense Health Plan Providers
FROM: Well Sense Health Plan
SUBJECT: **Policy and Prior Authorization Program Changes**

Pharmacy Benefit Updates

The following drugs will require **prior authorization** under specific clinical pharmacy policies effective June 1, 2021:

- DayVigo
- Epidiolex
- Fintepla
- Ingrezza
- Kesimpta
- Kynmobi
- Nayzilam
- Nurtec ODT
- Pretomanid
- Reyvow
- Sirturo
- Valtoco
- Vyepti
- Ubrelvy
- Xywav
- Zeposia
- posaconazole tablet

The following drugs will be **covered without a prior authorization** effective June 1, 2021:

- Anjesco (covered on the medical benefit side only)
- dimethyl fumarate
- Rukobia
- Cabenuva

The following drugs will have **quantity limit** changes effective June 1, 2021:

- diazepam rectal
- Diastat

The following drug will be **non-formulary** effective June 1, 2021:

- Noxafil tablet (Brand)

The following **clinical policies have been updated**, effective June 1, 2021:

- Antidepressants
- Antipsychotics
- Antifungal Agents
- Buprenorphine and Naloxone agents
- Botox
- CGRP
- Diacomit
- Hepatitis C
- Inbrija
- Insomnia Agents
- Multiple Sclerosis
- Narcolepsy
- Nuedexta
- Opioids
- Pregabalin and Lyrica/Lyrica CR
- Synagis
- Systemic Antibiotics
- VMAT 2 Inhibitors

Please visit the Pharmacy section of wellsense.org for complete policies and forms. The updated policies will be available in the Pharmacy Policies section at wellsense.org 30 days prior to the effective date.